Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PTIE
Previous Symbol
CUSIP69562K10
Phone512-501-2444
Debt
Debt-to-Equity RatioN/A
Current Ratio24.09
Quick Ratio24.09
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.47 per share
Price / Book0.74
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-11,910,000.00
Net MarginsN/A
Return on Equity-68.43%
Return on Assets-63.17%
Miscellaneous
Employees9
Outstanding Shares17,220,000
Market Cap$18.60 million
OptionableNot Optionable
Pain Therapeutics (NASDAQ:PTIE) Frequently Asked Questions
What is Pain Therapeutics' stock symbol?
Pain Therapeutics trades on the NASDAQ under the ticker symbol "PTIE."
When did Pain Therapeutics' stock split? How did Pain Therapeutics' stock split work?
Shares of Pain Therapeutics reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Pain Therapeutics stock prior to the reverse split would have 14 shares after the split.
How were Pain Therapeutics' earnings last quarter?
Pain Therapeutics, Inc. (NASDAQ:PTIE) announced its earnings results on Monday, October, 29th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.50. View Pain Therapeutics' Earnings History.
When is Pain Therapeutics' next earnings date?
Has Pain Therapeutics been receiving favorable news coverage?
Headlines about PTIE stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pain Therapeutics earned a daily sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Are investors shorting Pain Therapeutics?
Pain Therapeutics saw a increase in short interest in October. As of October 15th, there was short interest totalling 2,465,673 shares, an increase of 62.7% from the September 28th total of 1,515,735 shares. Based on an average trading volume of 9,596,167 shares, the days-to-cover ratio is currently 0.3 days. Approximately 17.0% of the company's stock are short sold. View Pain Therapeutics' Current Options Chain.
Who are some of Pain Therapeutics' key competitors?
Some companies that are related to Pain Therapeutics include Medicure (MCUJF), Innovate Biopharmaceuticals (INNT), Arcturus Therapeutics (ARCT), IMMUTEP LTD/S (IMMP), Alpine Immune Sciences (ALPN), Vaccinex (VCNX), BIOLINERX Ltd/S (BLRX), Alimera Sciences (ALIM), Oramed Pharmaceuticals (ORMP), NewLink Genetics (NLNK), Fortress Biotech (FBIO), KemPharm (KMPH), Immune Design (IMDZ), Elite Pharmaceuticals (ELTP) and Aptevo Therapeutics (APVO).
Who are Pain Therapeutics' key executives?
Pain Therapeutics' management team includes the folowing people:
- Mr. Remi Barbier, Founder, Chairman, CEO, Pres & Principal Financial Officer (Age 58)
- Dr. Nadav Friedmann, COO, Chief Medical Officer & Director (Age 75)
- Dr. Michael Marsman Pharm.D., Sr. VP of Regulatory Affairs
Who are Pain Therapeutics' major shareholders?
Pain Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include First Eagle Investment Management LLC (9.99%) and Renaissance Technologies LLC (1.52%). Company insiders that own Pain Therapeutics stock include Armistice Capital Master Fund, Armistice Capital, Llc and Sanford Robertson. View Institutional Ownership Trends for Pain Therapeutics.
Which major investors are buying Pain Therapeutics stock?
How do I buy shares of Pain Therapeutics?
Shares of PTIE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pain Therapeutics' stock price today?
One share of PTIE stock can currently be purchased for approximately $1.10.
How big of a company is Pain Therapeutics?
Pain Therapeutics has a market capitalization of $18.60 million. Pain Therapeutics employs 9 workers across the globe.
What is Pain Therapeutics' official website?
How can I contact Pain Therapeutics?
Pain Therapeutics' mailing address is 7801 NORTH CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The biopharmaceutical company can be reached via phone at 512-501-2444 or via email at [email protected]
MarketBeat Community Rating for Pain Therapeutics (NASDAQ PTIE)
MarketBeat's community ratings are surveys of what our community members think about Pain Therapeutics and other stocks. Vote "Outperform" if you believe PTIE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTIE will underperform the S&P 500 over the long term. You may vote once every thirty days.
